15 May , 2025 By : Debdeep Gupta
Shilpa Medicare share price extended gains on sixth consecutive session, rising 3 percent in the opening trade on May 15 following the company received Establishment Inspection Report (EIR) from United State Food and Drug Administration (USFDA).
At 09:26am, Shilpa Medicare was quoting at Rs 715.55, up Rs 21.40, or 3.08 percent, on the BSE.
Shilpa Medicare's subsidiary, Shilpa Pharma Lifesciences, Unit-1 received EIR from USFDA and the site is classified as VAI.
The inspection was carried out at unit-1 by USFDA between March 3-7, 2025.
Earlier in this month, company's biologics arm Shilpa Biologics site at Dharwad, Karnataka, has received its European GMP certification for manufacturing of test batches based on the inspection between February 18-20, 2025, conducted by the competent authority of Austria. The inspection was closed with Zero observations.
In March, Shilpa Biologicals, entered into a binding term sheet with Switzerland-based mAbTree Biologics AG for the development, manufacture, marketing, and sale of a new biological entity (NBE).
The share touched a 52-week high of Rs 959.95 and a 52-week low of Rs 419.10 on 18 September, 2024 and 04 June, 2024, respectively.
Currently, the stock is trading 25.46 percent below its 52-week high and 70.73 percent above its 52-week low.
The market capitalisation of the company stands at Rs 6,997.43 crore.
The share price rose 41 percent in the last one-year.
0 Comment